Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene - PubMed (original) (raw)

. 1997 Dec 15;57(24):5564-70.

Affiliations

• PMID: 9407968

Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene

E P Böttinger et al. Cancer Res. 1997.

Abstract

To test the hypothesis that the transforming growth factor-beta (TGF-beta) system has tumor suppressor activity in the mammary gland, we have generated transgenic mice overexpressing a dominant-negative mutant form of the type II TGF-beta receptor, under the control of the mouse mammary tumor virus-long terminal repeat. High-level expression of the transgene was observed in the mammary and salivary glands, with lower expression in the lung, spleen, and testis. Older nulliparous transgenic mice (9-17 months) showed a marked increase in the incidence and degree of lobulo-alveolar side-branching in the mammary glands when compared to wild-type littermates (24.8% of glands examined histologically versus 14.4%; P = 0.004), suggesting a role for endogenous TGF-betas in regulating development or maintenance of mammary alveoli. Spontaneous tumorigenesis was unchanged in the transgenic mice. However, following initiation with the carcinogen 7,12-dimethylbenz[a]anthracene, the transgenic group showed a significant increase in the incidence and multiplicity of mammary tumors when compared with wild-type littermates (40% incidence in transgenic mice versus 22% for wild-type, with 4 of 25 transgenics developing multiple mammary tumors versus 0 of 27 wild-type; P = 0.03). An early increase in the incidence of lung tumors was also observed in transgenic mice, but no difference between genotype groups was seen in the incidence of tumors in tissues in which the transgene is not expressed. The data show that the endogenous TGF-beta system has tumor suppressor activity in the mammary gland and lung.

PubMed Disclaimer

Similar articles

• Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
  Crowley MR, Frost A, Chen DT, Baffi MO, Nicola T, Serra R. Crowley MR, et al. Differentiation. 2006 Feb;74(1):40-52. doi: 10.1111/j.1432-0436.2006.00056.x. Differentiation. 2006. PMID: 16466399
• A transgenic mouse model for mammary carcinogenesis.
  Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, Rosen JM. Li B, et al. Oncogene. 1998 Feb 26;16(8):997-1007. doi: 10.1038/sj.onc.1201621. Oncogene. 1998. PMID: 9519874
• TGF beta regulation of cell proliferation.
  Moses HL, Arteaga CL, Alexandrow MG, Dagnino L, Kawabata M, Pierce DF Jr, Serra R. Moses HL, et al. Princess Takamatsu Symp. 1994;24:250-63. Princess Takamatsu Symp. 1994. PMID: 8983080 Review.
• Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia.
  Schroeder JA, Lee DC. Schroeder JA, et al. J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):119-29. doi: 10.1023/a:1026347629876. J Mammary Gland Biol Neoplasia. 1997. PMID: 10882298 Review.

Cited by

• C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer.
  Strathearn LS, Spender LC, Schoenherr C, Mason S, Edwards R, Blyth K, Inman GJ. Strathearn LS, et al. Cells. 2024 Sep 12;13(18):1530. doi: 10.3390/cells13181530. Cells. 2024. PMID: 39329715 Free PMC article.
• SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
  Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C, Deng L, Wang B, Pan Y, Li P. Luo J, et al. Breast Cancer Res. 2022 Dec 29;24(1):99. doi: 10.1186/s13058-022-01596-y. Breast Cancer Res. 2022. PMID: 36581908 Free PMC article. Review.
• The p53 Family Members p63 and p73 Roles in the Metastatic Dissemination: Interactions with microRNAs and TGFβ Pathway.
  Rodriguez Calleja L, Lavaud M, Tesfaye R, Brounais-Le-Royer B, Baud'huin M, Georges S, Lamoureux F, Verrecchia F, Ory B. Rodriguez Calleja L, et al. Cancers (Basel). 2022 Dec 1;14(23):5948. doi: 10.3390/cancers14235948. Cancers (Basel). 2022. PMID: 36497429 Free PMC article. Review.
• Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin.
  Tewari D, Priya A, Bishayee A, Bishayee A. Tewari D, et al. Clin Transl Med. 2022 Apr;12(4):e795. doi: 10.1002/ctm2.795. Clin Transl Med. 2022. PMID: 35384373 Free PMC article. Review.
• SMAD7 enhances adult β-cell proliferation without significantly affecting β-cell function in mice.
  Sehrawat A, Shiota C, Mohamed N, DiNicola J, Saleh M, Kalsi R, Zhang T, Wang Y, Prasadan K, Gittes GK. Sehrawat A, et al. J Biol Chem. 2020 Apr 10;295(15):4858-4869. doi: 10.1074/jbc.RA119.011011. Epub 2020 Mar 2. J Biol Chem. 2020. PMID: 32122971 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)